Bupivacaine HCl 0.375% w/v and Lidocaine HCl 2% w/v Solution for Retrobulbar or…
Recall D-1514-2022, part of FDA recall event 90854. See Pine Pharmaceuticals's company page.
Pine Pharmaceuticals, LLC started this Class II drug recall on Jul 27, 2022 (voluntary: firm initiated); FDA lists it as terminated, terminated Oct 19, 2022.
- Classification: Class II
- Started: Jul 27, 2022
- Status: Terminated
Lack of Assurance of Sterility
- Product
- Bupivacaine HCl 0.375% w/v and Lidocaine HCl 2% w/v Solution for Retrobulbar or Peribulbar Injection; packaged in a) 10 mL prefilled syringe, Item# 803, barcode 6919408031; b) 5 mL prefilled syringe, Item# 933, barcode 6919409331, Rx only, Pine Pharmaceuticals, 355 Riverwalk Parkway, Tonawanda, NY 14150.
- Quantity
- a) 920 syringes; b) 3263 syringes
- Lots and codes
- Lot #s: a) 58366, exp. date 09/26/2022; 60247, exp. date 12/04/2022; b) 54825, exp. date 08/10/2022; 57583, exp. date 08/22/2022; 59343, exp. date 10/30/2022; 60355, exp. date 10/11/2022
- Distribution
- Product was distributed to direct accounts in AL, CA, NC and NY
- Recalling firm
- Pine Pharmaceuticals, LLC, Tonawanda, NY, United States
- How the firm notified
- Letter
- FDA classified
- Sep 15, 2022
Newest first, one product per recall event; search them all
- Tropi-Phen (tropicamide 1%, phenylephrine 2.5%) ophthalmic solution, 5mL multi-use dropper, Rx only, Compounded by Pine…D-0063-2024 · Class II · Oct 2, 2023 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports